首页> 外文OA文献 >Circulating APRIL levels are correlated with advanced disease and prognosis in rectal cancer patients
【2h】

Circulating APRIL levels are correlated with advanced disease and prognosis in rectal cancer patients

机译:循环APRIL水平与直肠癌患者的晚期疾病和预后相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have previously shown that the tumor necrosis factor family member a proliferation-inducing ligand (APRIL) enhances intestinal tumor growth in various preclinical tumor models. Here, we have investigated whether APRIL serum levels at time of surgery predict survival in a large cohort of colorectal cancer (CRC) patients. We measured circulating APRIL levels in a cohort of CRC patients (n = 432) using a novel validated monoclonal APRIL antibody (hAPRIL.133) in an enzyme-linked immunosorbent assay (ELISA) setup. APRIL levels were correlated with clinicopathological features and outcome. Overall survival was examined with Kaplan-Meier survival analysis, and Cox proportional hazards ratios were calculated. We observed that circulating APRIL levels were normally distributed among CRC patients. High APRIL expression correlated significantly with poor outcome measures, such as higher stage at presentation and development of lymphatic and distant metastases. Within the group of rectal cancer patients, higher circulating APRIL levels at time of surgery were correlated with poor survival (log-rank analysis P-value 0.008). Univariate Cox regression analysis for overall survival in rectal cancer patients showed that patients with elevated circulating APRIL levels had an increased risk of poor outcome (hazard ratio (HR) 1.79; 95% confidence interval (CI) 1.16-2.76; P-value 0.009). Multivariate analysis in rectal cancer patients showed that APRIL as a prognostic factor was dependent on stage of disease (HR 1.25; 95% CI 0.79-1.99; P-value 0.340), which was related to the fact that stage IV rectal cancer patients had significantly higher levels of APRIL. Our results revealed that APRIL serum levels at time of surgery were associated with features of advanced disease and prognosis in rectal cancer patients, which strengthens the previously reported preclinical observation of increased APRIL levels correlating with disease progression
机译:我们以前已经表明,肿瘤坏死因子家族成员增殖诱导配体(APRIL)在各种临床前肿瘤模型中增强了肠道肿瘤的生长。在这里,我们调查了手术时APRIL血清水平是否可预测大肠直肠癌(CRC)患者的生存率。我们在酶联免疫吸附测定(ELISA)装置中使用新型经过验证的单克隆APRIL抗体(hAPRIL.133)测量了一组CRC患者(n = 432)的循环APRIL水平。 APRIL水平与临床病理特征和预后相关。通过Kaplan-Meier生存分析检查总体生存,并计算Cox比例风险比。我们观察到循环APRIL水平在CRC患者中呈正态分布。较高的APRIL表达与不良的预后指标显着相关,例如淋巴和远处转移的出现和发展阶段较高。在直肠癌患者组中,手术时较高的循环APRIL水平与不良的生存率相关(对数秩分析P值0.008)。直肠癌患者总生存的单变量Cox回归分析显示,循环APRIL水平升高的患者预后不良的风险增加(危险比(HR)1.79; 95%置信区间(CI)1.16-2.76; P值0.009) 。直肠癌患者的多变量分析表明,APRIL作为预后因素取决于疾病的分期(HR 1.25; 95%CI 0.79-1.99; P值0.340),这与IV期直肠癌患者的预后显着相关。更高级别的APRIL。我们的结果表明,手术时APRIL血清水平与直肠癌患者的疾病进展和预后相关,这加强了先前报道的临床前观察到的与疾病进展相关的APRIL水平升高

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号